Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of AK117 plus azacitidine and venetoclax in acute myeloid leukemia
CTR20241395Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ligufalimab, azacitidine, venetoclax in acute myeloid leukemia (AML), sponsored by Akeso, Inc.. Started Jun 2024; status: active.
02
Drugs
ligufalimabazacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20241395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241395.